The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has issued a warning to users of weight loss injections, specifically Ozempic and Wegovy, regarding a rare and serious side effect known as non-arteritic anterior ischemic optic neuropathy (NAION), which may result in sudden blindness. This warning came after singer Robbie Williams reported experiencing worsening vision believed to be associated with these medications. The MHRA emphasized that consumers should seek immediate medical attention if they experience blurred or clouded vision.

NAION is a condition that leads to sudden vision loss in one eye due to diminished blood supply to the optic nerve. The agency's alert specifically targets individuals using semaglutide-based drugs, which are marketed under the names Wegovy for weight loss and Ozempic for Type 2 diabetes treatment. Officials are urging healthcare professionals to be vigilant and to advise patients on the potential risks related to these injections.

The rising popularity of weight loss jabs like Wegovy has raised concerns among health regulators, prompting warnings about their serious side effects alongside benefits. As these medications become increasingly prescribed, the emphasis on monitoring for rare but severe complications like NAION is critical, especially given the growing number of individuals using these drugs for weight management. The revelation raises questions about the safety of such treatments and the need for robust regulatory oversight in the rapidly evolving landscape of pharmacological weight management options.